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ORIGINAL ARTICLEEvaluation of Prognostic Factors Associated With Differentiated
Thyroid Carcinoma With Pulmonary MetastasisMohsen Qutbi, MD,* Babak Shafeie, MD,* Mahasti Amoui, MD,† Faraj Tabeie, PhD,*
Zahra Azizmohammadi, MD,* Ali Mahmoud-Pashazadeh, MSc,‡ Hamid Javadi, MD,§
Majid Assadi, MD,‡ and Isa Neshandar Asli, MD*Background: Because one of the major sites for metastasis of thyroid can-
cers is the lung, studying the pattern of pulmonary metastasis may provide
useful information for the effective treatment of these patients. In this study,
by assessing the metastasis pattern, we aimed to identify the factors that may
affect prognosis and response to treatment in patients with differentiated thy-
roid carcinoma (DTC) with pulmonary metastasis.
Methods: This retrospective study included 75 patients with DTC with pul-
monary metastasis whowere referred to our nuclear medicine section over a
period of 10 years. The data obtained were analyzed with regard to response
to treatment to assess the effects of the included factors on prognosis.
Results: Of the 1746 patients referred to our section, 75 (4.3%) had pulmo-
nary metastasis. According to the pattern of pulmonary metastasis, they were
divided into 4 groups: nodular, diffuse, combined, and other. The mean age
of the patients was 43.8 ± 18.5 years. After the follow-up, 58 patients sur-
vived, 14 of whom responded to the treatment. The mean number of radio-
iodine therapy sessions that the patients received was 3.2 ± 2, and the mean
cumulative dose was 554.7 ± 387.8 mCi. Statistical analysis of the data re-
vealed that there was no significant difference in the response to treatment
between patients with different patterns of pulmonary metastasis (P > 0.3).
However, significant differences were reported in the response to treatment
between patients with papillary thyroid carcinoma and those with follicular
thyroid carcinoma (P < 0.03). The 1-, 5-, and 9-year survival rates were re-
ported as 98%, 76%, and 51%, respectively.
Conclusions: Patients with DTC with pulmonary metastasis have a rela-
tively favorable prognosis and response rate, as well as longer survival.
The type of DTC is the only factor that affects the response to treatment.
KeyWords: differentiated thyroid cancer, prognosis, pulmonary metastasis,
response to treatment
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D ifferentiated thyroid carcinoma (DTC) is of the most curableendocrine cancers; it can be classified as papillary thyroid car-
cinoma (PTC) and follicular thyroid carcinoma (FTC). This is a slowly
progressing disease that has been reported to have a 10-year sur-
vival rate of more than 80%.1 The reported incidence of DTC has
been increasing worldwide; this is partly attributable to theReceived for publication March 10, 2016; revision accepted September 8, 2016.
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sensitivity diagnosis feasible and partly attributable to exposure to
radiation in our environment as well as risky living habits.5,6 While
DTC is mainly limited to the thyroid gland, it has been reported that
distant metastasis, particularly pulmonary metastasis, occurs in 4%
to 23% of DTC patients,7–10 which may reduce the associated sur-
vival rate and prognosis. In some rare cases of DTC, the brain,
breast, liver, kidney, muscle, and skin are also involved. The pres-
ence of distant metastases is of pivotal importance for physicians,
because it can be an indicator of poor survival, as only half of the
patients who have metastasis may survive for more than 10 years.11
Several studies have been performed to assess the outcome
and prognosis of DTC patients with pulmonarymetastasis: age, thy-
roglobulin (Tg) levels cumulative dose of radioiodine, and size of
the tumor were found to be important prognostic factors.
As recognizing the patterns of pulmonary metastasis in DTC
patients has a major impact on the prognosis of patients and can
help physicians with their clinical decision making, the objective
of this study was to assess the pattern of metastasis and identify
the prognostic factors associated with survival and response to treat-
ment in DTC patients with pulmonary metastases.
MATERIALS AND METHODS
The current survey is a retrospective cross-sectional study
that assesses the prognostic value of the pattern of pulmonary me-
tastasis in DTC patients and its impact on outcome and response
to treatment with radioiodine.
The data for this study were extracted from the medical
records of DTC patients with pulmonary metastases who were
hospitalized at the Department of Nuclear Medicine of a tertiary
university-affiliated hospital between 2005 and 2015. We included
only DTC patients who underwent total thyroidectomy and received
a diagnosis of pulmonary metastasis based on posttreatment whole-
body scan or chest CT scan, chest radiography, or radioactive iodine
whole-body scan during follow-up. The disease status was moni-
tored by whole-body radioiodine scanning and measuring the se-
rum Tg level.
This study complies with the Declaration of Helsinki, and it
was approved by the institutional ethics committee of our university.
Statistical Analysis
All data are presented as the mean ± SD, with ranges given
when appropriate. Continuous variables were evaluated using the
unpaired t test, and categorical variables were evaluated using the χ2
analysis. A survival analysis using Kaplan-Meier test was also carried
out. To compare survival between groups, the log-rank test was applied.
P < 0.05 was considered to be statistically significant. The
SPSS for Windows software package (Release 22; SPSS Inc,
Chicago, Ill) was applied for the statistical analysis.
RESULTS
Of the 1746 patients who were referred to our nuclear medi-
cine section and hospitalized for DTC, 75 (4.3%) had pulmonary016 www.nuclearmed.com 917
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Qutbi et al Clinical Nuclear Medicine • Volume 41, Number 12, December 2016metastases and were included in this study. Of the 75 patients, 60
(80%) were female, and 15 (20%) were male (age, 13–79 years; mean
age, 43.8 ± 18.5 years). Based on the pathological characteristics of
the tumor, 61 patients (81.3%) received a diagnosis of PTC (46 fe-
males and 15 males), and 14 patients (18.7%) received a diagnosis
of FTC (all females). The average number of hospitalizations dur-
ing which radioiodine treatment was administered was 3.2 ± 2 (me-
dian, 3): it was 3.2 ± 1.9 for female patients and 3.1 ± 2.3 for male
patients. Moreover, the average number of hospitalizations (with ra-
dioiodine treatment) was 3.2 ± 2.1 in patients with PTC and
3.0 ± 1.2 in patients with FTC. The average cumulative dose was
554.7 ± 387.8 mCi (range, 100-1650mCi). The average cumulative
dose was 551 mCi in female patients and 566 mCi in male patients.
Moreover, it was 560 mCi in patients with PTC and 528 mCi in pa-
tients with FTC. Of the total patients, 67 patients (89.3%) were pos-
itive, and 8 patients (10.7%) were negative for cervical lymph node
involvement. Among the female patients, 55 patients (91.7%) were
positive, and 5 patients (8.3%) were negative for cervical lymph
node involvement. Furthermore, among the male patients, 12
(80%) were positive, and 3 (20%) were negative for cervical lymph
node involvement. Among patients with PTC, 55 (90.2%) were
positive, and 6 (9.2%) were negative for lymph node involvement,
and in patients with FTC, 12 patients (85.7%) were positive, and
2 (14.3%) were negative for lymph node involvement. With regard
to distant metastasis other than pulmonary metastasis, 16 patients
(21.3%) received a diagnosis of bone metastases, and 2 patients
(2.7%) received a diagnosis of liver metastasis. Among the female
patients, 10 (16.7%) had bone metastasis, and 2 (3.3%) had liver
metastasis. Among the male patients, 6 (40%) had bone metastasis
with no liver metastasis. Among the patients with PTC, 11 (18%) had
bone metastasis, and 1 (1.6%) had liver metastasis. Among the pa-
tients with FTC, 5 (35.7%) had bone metastasis, and 1 (7.1%) had
liver metastasis.With regard to the pattern of pulmonary metastasis,
42 patients (56%) had a diffuse pattern, 19 patients (25.3%) hadFIGURE 1. Survival rate of patients with DTC who present with p
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Copyright © 2016 Wolters Kluwer Hnodular involvement, and 11 (14.7%) had a combination of both;
the remaining 3 patients (4%) had other pattern. The diffuse pattern,
nodal involvement, and combination of both were observed in 34
(56.7%), 15 (25%), and 8 (13.3%) female patients, respectively,
and 8 (53.3%), 4 (26.7%), and 3 (20%) male patients, respectively;
and 34 (55.7%), 16 (26.2%), and 8 (13.1%) patients with PTC, re-
spectively, and 8 (57.1%), 3 (21.4%), and 3 (21.4%) patients with
FTC, respectively.
Of the total of 75 patients who were included because they
had pulmonary metastasis, 61 patients (81.3%) had pulmonary
metastasis at presentation; 14 patients (18.7%) had no sign of
pulmonary involvement, but at later stages of the disease, they
received a diagnosis of pulmonary metastasis. The interval be-
tween the diagnosis of DTC and diagnosis of pulmonary metastasis
was in the range of 6 to 48 months (mean, 12.6 ± 20.4 months;
median, 17 months).
Of the 75 patients, 58 were followed up, 14 of whom responded
to treatment, and 44 of whom did not respond to treatment. With re-
gard to the patients who responded to the treatment, the average
time from diagnosis of pulmonary metastasis to response to treat-
ment was 8 to 48 months (mean, 20.8 ± 13.6 months). In this dura-
tion, the patients underwent 1 to 7 sessions of iodine therapy (mean,
2.5 ± 1.6; median, 2). Moreover, in this duration, the cumulative
dose given to the patients ranged from 150 to 950 mCi (mean,
387.5 ± 214.4 mCi). With regard to the pattern of pulmonary in-
volvement in these patients, 6 had a diffuse pattern, 4 had nodular
involvement, and 4 had a combination of both.
Of the 58 patients who were followed up, 51 patients were
alive, and 7 patients had died at the end of the follow-up period.
Four patients died because of respiratory failure resulting from ex-
tensive pulmonary metastasis, 1 patient died because of extensive
myocardial infarction, one because of cerebral metastasis, and also
1 patient died because of multiple bone metastases. Furthermore,
of 4 patients who died as a result of respiratory failure, 2 patientsulmonary metastasis.
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 2. Survival rate of patients between 2 types of papillary and follicular thyroid cancer who present with pulmonary
metastasis.
Clinical Nuclear Medicine • Volume 41, Number 12, December 2016 DTC With Pulmonary Metastasishad bone metastases, and 1 had liver metastasis. There were no sig-
nificant differences in cause of death and other clinical and paraclinical
variables including age, sex, number of hospitalizations, average time
from diagnosis of pulmonary metastasis to response to treatment,
cumulative dose, the pattern of pulmonary involvement, being dis-
tant metastasis, and type of pathology of thyroid cancer (P > 0.05).FIGURE 3. Survival rate of patients with DTC according to the pu
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2016 Wolters Kluwer HStatistical analysis of the data revealed that there was no sig-
nificant difference in the response to treatment and also survival rate
between patients with different patterns of pulmonary involvement
(P > 0.3). A significant differencewas found in the response to treat-
ment between patients with PTC and patients with FTC (P < 0.03),
but the survival rate between them was not significant statisticallylmonary metastasis pattern.
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FIGURE 4. Outcome of radioiodine therapy in DTC patients
according to the metastasis pattern.
FIGURE 5. Response to radioiodine therapy in DTC patients
according to the metastasis pattern.
Qutbi et al Clinical Nuclear Medicine • Volume 41, Number 12, December 2016(P > 0.05). The 1-, 5-, and 9-year survival rates were 98%, 76%, and
51%, respectively (Figs. 1–3).
The outcomes of radioiodine therapy and response to treat-
ment, according to the type of pulmonary involvement, are shown
in Figures 4 and 5.
DISCUSSION
Given the importance of factors that affect the prognosis and
survival of DTC patients, more knowledge about these factors can
prove to be vital for better treatment planning, as well as improving
adherence to treatment.
In DTC patients, early detection and treatment have been
found to have a substantial effect on the survival rate of patients.
It has been reported that a significant proportion of these patients
have regional metastasis (20%-50%) and distant metastasis (3.3%-
6%).12,13 Metastasis not only reduces survival but also can adversely
affect the quality of life of these patients, who are mostly young.
The results of our study were in a good agreement with pre-
vious ones14; according to the previous findings, a considerable pro-
portion of patients have metastasis at the time of diagnosis of thyroid
cancers (81% vs 75%). The number of patients who had metastasis
at the time of diagnosis was higher in the FTC than in the PTC group.
This finding emphasizes the importance of measuring the Tg level
and radioiodine scanning in the first stages of the disease. In pa-
tients who present with pulmonary metastasis, involvement of the
cervical lymph node and distant metastasis to other regions are
more likely to occur.
To date, few, if any studies, have investigated the disease
course in DTC patients with pulmonary metastasis, and these stud-
ies have mainly focused on the response to treatment and survival.
In this study, we comprehensively assessed the disease course, in-
cluding the number of radioiodine therapy sessions, the total cumu-
lative dose that the patients received, and the amount of time required
to respond to treatment. In previous studies, the 5- and 10-year sur-
vival rates were bothmainly greater than 80%, but for FTC patients,
it was generally in the range of 40% to 50%. In contrast, in our
study, the 5- and 9-year survival rates were calculated as 76% and
51%, respectively. The main reason for the discrepancy in the sur-
vival rates reported by different studies is that the proportion of
FTC and PTC patients included in each study is different.
In our study, of the 75 patients who were followed up for an
average of 40months (range, 8-118 months), 14 (18.7%) responded920 www.nuclearmed.com
Copyright © 2016 Wolters Kluwer Hto treatment at the end of follow-up. Even though the proportion of
patients with FTC and those with PTC differed between previous
studies, in all the studies, the response to treatment wasmuch poorer
in FTC patients than in PTC patients. In the current study, there was
no statistically significant difference in response to treatment be-
tween men and women and between patients with different patterns
of pulmonary involvement; however, a significant difference in
treatment response was found between PTC and FTC patients.
Several studies have been conducted to investigate the out-
come and prognosis in DTC patients who present with pulmonary
metastasis. For example, in a previous survey, a follow-up study
was performed on 272 DTC patients over a 23-year period.14 Of
70 patients with pulmonary metastasis, 30 died during follow-up,
and only 4 achieved complete remission; furthermore, the 5-, 10-,
15-, and 20-year survival rates were reported as 68.5%, 54%,
41.6%, and 27.7%, respectively. In this previous survey, the most
important prognostic factors were age, Tg levels after surgery, cu-
mulative dose of radioiodine, and difference in the size of the tumor
between groups with and without pulmonary metastases. Based on
their findings, they concluded that pulmonary metastasis of FTC
weakens prognosis. A retrospective study was performed over a pe-
riod of more than 40 years to estimate the survival of 96 DTC pa-
tients with pulmonary metastases. It was observed that age younger
than 45 years, absorption of radioiodine by metastatic tissue, and
miliaric metastases were associated with longer survival.15 In an-
other study, 17 patients with diffuse and focal pulmonary metastasis
were followed up for 89 months to study their clinical presentation
and response to treatment.16 After the follow-up, 16 patients survived,
and only 1 patient died of unrelated causes. Furthermore, 6 patients
completely recovered at the end of the follow-up, and the pulmo-
nary metastasis disappeared completely in 8 patients. The required
dose for the treatment of pulmonary metastasis with a diffuse pat-
tern was more than that required for pulmonary metastasis with a
focal pattern. The authors concluded that the prognosis of patients
with PTC with small pulmonary metastases was good and that the
Tg level and small tumor size were associated with a better progno-
sis. The results of another study performed on 106 FTC patients
with metastasis showed that the 5-, 10-, and 15-year survival rates
were 82%, 63.8%, and 23.9%, respectively; furthermore, tumor size
and age of the patients at presentation were identified as the most
important prognostic factors.17
Regarding the cause of death, the current study revealed re-
spiratory failure as consequence of multiple pulmonary metastases
to be the most common cause of death in the patients, which is
matched with previous studies generally. In addition, there were© 2016 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
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paraclinical parameters, which in our study could be due to the small
number of patients who died. In a large study done by Kitamura
et al,18 the causes of death in 161 fatal cases of thyroid cancer in-
cluding 62 anaplastic carcinomas and 99 fatal differentiated car-
cinomas were analyzed. A single fatal condition was not
delineated in 55 patients. In the remaining 106 cases, respiratory
insufficiency (43%) was the most common specific fatal cause,
followed by circulatory failure (15%), hemorrhage (15%), and air-
way obstruction (13%).18
At last, it should be highlighted that our study has some
drawbacks. One of the limitations of the current study was the lack
of pathologic data in the records of the patients. Another limitation
was that the study duration was not sufficient for following up some
of the patients to monitor the disease course and response to treat-
ment. As DTC generally has a good prognosis, long follow-up pe-
riods are required for a better and comprehensive assessment of
some of the consequences, such as death.
CONCLUSIONS
This study demonstrated that DTC patients with pulmonary
metastasis have a relatively favorable prognosis and response rate,
as well as long survival. It also indicated that the type of DTC is
the only factor that affects the response to treatment in the studied
group of DTC subjects.
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